The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 3, 2000, Pages 94-110

  Van Den Heuvel Eibrink, M M ^a,b   Sonneveld, P ^b   Pieters, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Leukemia; Membrane transport; Multidrug resistance proteins; Prognosis

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; EPIPODOPHYLLOTOXIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; VINCA ALKALOID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG TRANSPORT; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; PROGNOSIS; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0034012773     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp38094     Document Type: Review

References (183)

1. Abbaszadegan MR, Flutscher BW, Klimecki WT, List A, Dalton WS 1994 Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 54: 4676-4579
2. Advani R, Saba R, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Villena, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL 1999 Treatment of refractory and relapsed acute myelogeneous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93: 787-795
3. Asselin BL, Kreisman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ 1999 Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 21: 6-12
4. Aszalos A and Ross DD 1998 Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res 18: 2937-2944
5. Aszalos A, Thompson K, Yin J, Ross D 1999 Combinations of P-glycoprotein blockers, verapamil, PSC 833, and cremophor act differently on the multidrug resistance-associated protein (MRP) and on P-glycoprotein. Anticancer Res 19: 1053-1064
6. Baas F, Jongsma APM, Broxterman HJ, Arceci RJ, Housman D, Scheffer GL, Riethorst A, Van Groeningen M, Nieuwint AWM, Joenje H 1990 Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res 50: 5392-5398
7. Baer MR, Swann VL, Strollo NM, Carver AJ, Minderman Y, Rustum Y, Stewart CC 1998 Frequent coexistence of multidrug resistance in acute myeloid leukemia cells. Blood 92: 181-264
8. Beck WT, Handgrettinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V 1995 Expression of mdr1, mrp, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematol 89: 356-363
9. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalto WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivatava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R 1996 Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010-3020
10. Beck J, Handgretinger R, Klingebiel T, Dopfer R, Schaich M, Ehninger G, Niethammer D, Gekeler V 1996 Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia 10: 426-433
11. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA 1998 Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 103: 1083-1091
12. Boutonnat J, Bonnefoix T, Mousseau M, Seigneurin D, Ronot X 1998 Co-expression of multidrug resistance involved proteins: a flow-cytometric analysis. Anticancer Res 18: 2993-3000
13. Brophy NA, Marie JP, Rajas VA, Warnke RA, McFall PJ, Smith SD, Sikic BI 1994 Mdr-1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia 8: 327-335
14. Broxterman HJ, Schuurhuis GJ 1997a Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukemia. J Intern Med 242: 147-151
15. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Wahrer DCR, Ossenkoppele GJ, Schuurhuis GJ 1997b Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 11: 1110-1118
16. Broxterman HJ, Sonneveld P, Pieters R, Lankelma J, Eekman CA, Loonen AH, Ossenkoppele GJ, Lowenberg B, Pinedo HM, Schuurhuis GJ 1999 Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia 13: 258-265
17. Burger H, Nooter K, Zaman GJR, Sonneveld P, Van Wingerden KE, Oostrum RG, Stoter G 1994 Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8: 990-997
18. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsumo T, Tronchy J, Treille D, Fiere D 1992 Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells and diagnosis. Blood 79: 473-476
19. Campos L, Oriol P, Sabido O, Gyotat D 1997 Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk Lymphoma 27: 119-125
20. Chaudary PM. Roninson IB 1992 Activation of the MDR-1 (P-glycoprotein) gene expression by protein kinase C agonists. Oncol Res 4: 281-290
21. Chen YN, Mickley LA, Schwartz AM, Action EM, Hwang H. Fojo AT 1990 Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265: 10073-10080
22. Childs S, Yeh RL, Georges E Ling V 1995 Identification of a sister-gene to P-glycoprotein. Cancer Res 55: 2029-2034
23. Chugani DC, Rome LH and Kederaha NL 1993 Evidence that ribonucleoprotein particles are localized to the nuclear pore complex. J Cell Sci 106: 23-29
24. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Steward AJ, Kurz EU, Duncan AMV, Deeley RG 1992 Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654
25. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G. Bruno A, Masi M, Tabilio A, Pupa 1996 Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 8: 388-394
26. Del Poeta G, Venditta A, Aronica G, Stasi R, Cox CM, Buccisano F, Bruno A, Tamburini A, Suppo G, Simone MD, Epiceno AM, Del Moro B, Masa M, Papa G, Amadori S 1997a P-glycoprotein expression in de novo acute myeloid leukemia. Leuk Lymphoma 27: 257-274
27. Del Poeta G, Stasi R, Aronica G, Venditti A., Cox MC, Bruno A, Buccisano F, Masi M. Tribalto M, Amadori S, Papa G 1997b Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87: 1997-2004
28. Den Boer ML, Pieters R, Kazemier K, Rottier MMA, Scheper RJ, Flens MJ, Janka-Schauh GE, Veerman AJP 1996 LRP but not P-gp or MRP may cause drug resistance in childhood ALL. Proc Am Assoc Cancer Res 37: 319
29. Den Boer ML, Zwaan CM, Pieters R, Kazemier KM, Rottier MMA, Flens MJ, Scheper RJ, Veerman AJP 1997 Optimal immunocytochemical and flow-cytometric detection of P-gp, MRP, and LRP in childhood acute lymphoblastic leukemia. Leukemia 11: 1078-1085
30. Den Boer ML, Pieters R, Kazemier K, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schauh G, Creitzig U, Scheper RJ, Veerman AJP 1998a Relationship between major vault protein/lung resistance protein, P-glycoprotein expression and drug resistance in childhood leukemia. Blood 91: 2092-2098
31. Den Boer ML, Pieters R, Veerman A 1998b Mechanisms of cellular anthracyclin resistance in childhood acute leukemia. Leukemia 12: 1657-1670
32. Den Boer ML, Pieters R, Kazemir KM, Janka-Schrauh GE, Henze G, Veerman AJ 1998c The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood leukemia. Leukemia 12: 912-920
33. Dhooge C, De Moerloose B, lauteys G. Kint J, Ferster A, De Bacquer D, Philippe J. Benoit 1999 P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukemia: results of a 6-year prospective study. Br J Haematol 105: 676-683
34. Dayle LA, Kaufman SH, Fojo AT, Bailey CL, Gazdar AF 1993 A novel 95 kilodalton membrane polypeptide associated with lung cancer drug resistance. Lung Cancer 9: 317-326
35. Doyle LA, Yong Ming GAO, Yang W. Ross DD 1995a Characterization of a 95 kilodalton membrane glycoprotein associated with multidrug resistance. Int J Cancer 62: 593-598
36. Doyle LA, Ross DD, Sridhara R, Fojo AT, Kaufman SH, Lee EJ, Schiffer CA 1995b Expression of a 95 kDa membrane protein is associated with low daunomycin accumulation in leukemic blasts. Br J Cancer 71: 52-58
37. Doyle LA, Yang W, Rishi AK, Gao Y, Ross DD 1996 H19gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein. Cancer Res 56: 2904-2907
38. Dow LW, Dahl GV, Kalwinxky DK, Miro J, Nash MB, Roberson PK 1986 Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia. Blood 68: 400-405
39. Drenou B, Amiot L. Lamy T, Le Prise PY, Fauchet R 1998 Multidrug resistance in aggresssive lymphoproliferative disorders of T- and natural-killer origin. Leuk Lymphoma 30: 381-387
40. Endicott JA, Ling V 1990 The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58: 137-171
41. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, Broxterman HJ 1995 Functional detection of MDR1/P 170 and MRP/P190 mediated multidrug resistance in tumor cells by flowcytometer. Br J Cancer 72: 542-549
42. Filipits M, Suchomel RW, Zochbauer M, Brunner R, Lechner K, Pirker R 1997 Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 3: 1419-1425
43. Filipits M, Pohl G, Stranzl, Suchomel RW, Scheper RW, Jäger U, Geissler K, Lechner K, Pirker R 1998 Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91: 1508-1513
44. Flens MJ, Izquirdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ, Zaman GJR 1994 Immunochemical detection of the multidrug resistance-associated protein (MRP) in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 54: 4557-4563
45. Fojo AT, Ueda K. Slamon DJ, Poplack DG, Gottesman MM, Pastan I 1987 Expression of a multi-drug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265
46. Gala JL, Lachlan JM, Belt DR, Michaux JL, Ma DDF 1994 Specificity and sensitivity of immunocyto-chemistry for detecting P-glycoprotein in haematologic malignancies. J Clin Pathol 47: 619-624
47. Gazitt Y, Lee DY, Wang ME, Boldt DH 1998 Functional mdr-1 expression in adult acute lymphoblastic leukemia (ALL). Blood 92: 676a
48. Gekeler V, Frese G, Noller A, Handgrettinger R, Wilisch A, Schmidt H, Muller CP, Dopfer R. Klingebiel T, Diddens H, Probst H, Niethammer D 1992 Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase π gene expression in primary and relapsed state adult and childhood leukemias. Br J Cancer 66: 507-517
49. Gekeler V Beck J, Noller A, Wilisch A, Frese G, Neuman M, Handgretinger R, Ehninger G, Probst H, Niethammer D 1994 Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol 69 (Suppl 1): S19-24
50. Georges E, Bradley G, Gariepy J, Ling V 1990 Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87: 152-156
51. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperreon J, Fauchet R 1993 Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81: 2394-2398
52. Goasguen JE, Lamy T, Bergeron C, Ly Sunaram B, Mordetet E, Gorre G, Dossot JM, Le Gall E, Grosbois B, Le Prise PY, Faughet R 1996 Multifactorial drug resistance phenomenon in acute leukemias: impact of P170-MDR1, LRP56 protein, glutathion-transferases and methallothione systems on clinical outcome. Leuk Lymphoma 23: 567-576
53. Guerci A, Merlin JL, Missoum N, Feldman L, Marchal S, Witz F, Rose C, Guerci O 1995 Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flowcytometry. Blood 85: 2147-2153
54. Gurbuxani S, Zhou D, Siminon G, Raina V, Arya LS, Sazawal S, Marie JP, Bhargava A 1998 Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India. Ann Hematol 76: 195-200
55. Hart SM, Ganeshagunt K, Hoffbrand AV, Prentice HG, Mehta AB 1994 Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 8: 2163-2168
56. Hart SM, Ganeshuuru K, Scheper RJ, Prentice HG, Hoffbrand AV, Mehta AB 1997 Expression of the human major vault protein (LRP) in acute myeloid leukemia. Exp Hematol 25: 1227-1232
57. Hegewisch-Becker S and Hossfeld DK 1996 The mdr phenotype in hematologic malignancies: prognostic relevance and future perspectives. Ann Hematol 72: 105-117
58. Herwijer H, Sonneveld P, Baas F, Nooter K 1990 Expression of mdr1 and mdr3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporin. J Natl Cancer Inst 28: 1133-1140
59. Higgins CF 1992 ABC transporters - from microorganisms to man. Ann Rev Cell Biol 8: 67-113
60. Higgins CF, Gottesman MM 1992 Is the multidrug transporter a flippase? Trends Biochem Sci 17: 18-21
61. Hipfner DR, Qincheng M. Leslie EM, Gao M. Deeley RG, Cole SPC 1999 Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. J Biol Chem 274: 15420-15426
62. Hollo Z, Homolya L, Hegedus T, Muller M, Szakacs G, Jakab K, Antal F, Sarkadi B 1998 Parallel functional and immunolocgical detection of human multidrug resistance proteins, P-glycoprotein and MRP1. Anticancer Res 18: 2981-2988
63. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA 1989 Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia. Br J Haematol 72: 40-44
64. Holmes JA, WestRR, Whittaker JA, Jacobs A 1991 Correlation of mdr status with clinical outcome in patients with acute myeloblastic leukemia. Br J Haematol 77: 130-131
65. Holmes JA and West RR 1994 The effect of MDR-1 gene expression on outcome in acute myeloid leukemia. Br J Cancer 69: 382-384
66. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R 1997 In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89: 2959-2965
67. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K 1997 Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11: 253-257
68. Hunault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M, Perrot JY, Levy V, Rio B, Cymbalista F, Zittoun R, Marie JP 1997 Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction chemotherapy. Ann Hematol 74: 65-71
69. Hyde SC, Emsley P, Hartshorn MJ, Mimmack, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, Higgins CF 1990 Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346: 362-365
70. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, Ezaki K, Hirano M 1994 Expression of P-glycoprotein in de novo acute myelogeneous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 8: 1492-1497
71. Ivy SP, Smith JK, Speciale A. Sather H, Hammond GD, Reaman GH 1992 Detection of mdr1 gene expression using polymerase chain reaction (PCR) in childhood acute lymphoblastic leukemia (ALL) at diagnosis. Proc Am Assoc Cancer Res 33: 473a
72. Ivy SP, Sather HN, Hammond GD, Reaman GH 1993 The prognostic significance of MDR1 gen expression at diagnosis in childhood acute lymphoblastic leukemia. Pediatr Res 33: 141a
73. Ivy SP, Olhefsky, Taylor BJ, Patel KM, Reaman GH 1996 Correlation of P-glycoprotein expression and function in childhood acute leukemia. Blood 88: 309-318
74. Izquierdo MA, Neefjes JJ, Mathari AEL, Flens MJ, Scheffer GL, Scheper RJ 1996 Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer 74: 1961-1967
75. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D 1994 ATP-dependent transport of gluthatione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54: 4833-4836
76. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Keppler D 1996 Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988-994
77. Johnson PRE, Hunt LP, Liu JA 1993 Prognostic factors in elderly patients with acute myeloid leukemia: development of a model to predict survival. Br J Haematol 85: 300-306
78. Kaczorowski S, Ochocka M, Aleksandrowicz R, Kaczorowska M, Matysiak M, Karwachi M 1996 Expression of P-glycoprotein in children and adults with leukemia-correlation with clinical outcome. Acute Leukemia V: 101-107
79. Kanerva J, Tirkainen M, Makipernaa A, Riikonen P, Mottonen, Salmi TT, Krusius T, Saarinen-Pikhkala UM 1998 Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol 15: 11-21
80. Kasimir-Bauer S, Ottinger H, Meusers P, Beelen DW, Brittinger G, Seeber S, Scheulen ME 1998 In acute myeloid leukemia, co-expression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and the heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 26: 1111-1117
81. Kaspers GJL, Veerman AJP, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, Van der Does-Van den Berg 1997 In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90: 517-530
82. Kingreen D, Sperling C, Notter, M, Scmidt C, Diddens H, Riehm H, Thiel E, Ludwig WD 1992 Sequential analysis of P-glycoprotein expression in childhood acute lymphoblastic leukemia. Hematol Blood Transfus 34: 23-28
83. Klumper E, Pieters R, Veerman AJP, Huismans D, Loonen A, Kaspers G, Höhlen K, Van Wering ER, Hartman R, Henze G 1995 In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86: 3861-3868
84. Knutsen T, Mickley LA, Ried T, Green ED, Manoir S du, Schrock E, Macville M, Ning Y, Robey R, Polymeropoulos M, Torres R, Fojo T 1998 Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 23: 44-54
85. Kool M, De Haas, Scheffer GL, Scheper RJ, Van Eijk MJT, Juijn JA, Baas F, Borst P 1997 Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5. Homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547
86. Kuss BJ, Deeley RG, Cole SP, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA 1994 Deletion of gene for multidrug resistance in acute myeloid leukemia with inversion in chromosome 16: prognostic implications. Lancet 343: 1531-1534
87. Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Kodama M, Iwasshi M, Arima T, Akiyama SI 1990 Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 66: 868-873
88. Legrand O, Perrot J, Tang R, Siminin G, Gurbuxani S, Zittoun R, Marie JP 1996 Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. Br J Haematol 94: 23-33
89. Legrand O, Siminon G, Zittoun R, Marie JP 1997 Comparison of MDR1, MRP, and LRP expression with in vitro drug sensitivity and in vivo response to treatment in fresh blast cells from adult acute myeloid leukemia. Blood 90: 180a
90. Legrand O, Simonin G, Zittoun R, Marie JP 1998a Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 12: 1367-1374
91. Legrand O, Simonin G. Zittoun R, Marie JP 1998b Both P-gp and MRP contribute to drug resistance in AML. Leukemia 12: 1327-1328
92. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP 1998c Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91: 4480-4488
93. Legrand O, Zittoun R, Marie JP 1999 Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 13: 578-584
94. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL 1995 Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flowcytometry: identification of discordant MDR-/Efflux+ and MDR+/ Efflux- cases. Blood 86: 2329-2342
95. Leith CP, Kopecky KJ, Chen IM, Slovak M, Head DR, Weick J, Appelbaum FR, Willman CL 1997 Frequency and clinical significance of expression of the multidrug resistance proteins MDR1, MRP1 and LRP in acute myeloid leukemia patients less than 65 years old. Blood 90: 389a
96. Leith C 1998 Multidrug resistance in leukemia. Curr Opin Hematol 5: 287-291
97. Lepelley P, Poulain S, Grardrel N, Peudhomme C, Cosson A, Fenaux P 1998 Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplatic syndromes. Leuk Lymphoma 29: 547-551
98. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W 1993 Phase I/II trial of cyclosporin as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660
99. List AF 1996a Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10: 937-942
100. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Woll SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS 1996b Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464-2469
101. Lohri A, Van Hille B, Bacchi M, Fopp M, Joncourt F, Reuter J, Cerny T, Fey MF, Herrmann R 1997a Five putative drug resistance parameters (MDR1/P-glycoprotem, MDR-1 associated protein, gluthatione-S-transferase, bcl-2 and topoisomerase 11 alpha) in 57 newly diagnosed acute myeloid leukemias. Swiss Group for Clinical Cancer Research (SAKK). Eur J Haematol 59: 206-215
102. Lohri A, Van Hille B, Reuter J, Tichelli A, Herrmann R 1997b mRNA expression, measured by quantitative reverse transcriptase polymerase chain reaction, of five putative drug resistance parameters, in normal and leukemic peripheral blood and bone marrow. Acta Haematol 98: 1-7
103. Longhurst TJ, O'Neill GM, Harvie RM, Davey RA 1996. The anthracyclin resistance-associated (ara) gene, a novel gene associated with multidrug resistance in a human leukaemia cell line. Br J Cancer 74: 1331-1335
104. Lowenherg B, Sonneveld P 1998 Resistance to chemotherapy in acute leukemia. Curr Opinion Oncol 10: 31-35
105. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI 1992 Alteration of etoposide pharmacokinetics and pharmacodynamics by ciclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642
106. Malayeri R, Filipits M, Suchomel RW, Zochbauer S, Lechner K, Piker R 1996 Multidrug resistance in leukemias and its reversal. Leuk Lymphoma 23: 451-458
107. Marie JP, Zittoun R, Sikic BI 1991 Multidrug resistance (mdr-1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood 78: 586-592
108. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R 1993a Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr-1 expression. Leukemia 7: 825-831
109. Marie JP, Bastie JN, Colom F, Faussat Suberville AM, Delmer A, Rio B, Delmas-Marsalat B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R 1993b Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 7: 821-824
110. Marie JP, Zhou DC, Guruxani S, Legrand O, Zittoun R 1996 MDR-1/P-gp in haematological neoplasms. Eur J Cancer 32A: 1034-1038
111. Marie JP 1997 Debate round-table: phenotyptic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice. Leukemia 11: 1063-1186
112. Martinez A, San Miguel JF, Valverde B, Barez A, Moro MJ, Garcia-Marcos MA, Perez-Simon JA, Vidriales, Orfao A 1998 Functional expression of MDR-1 in acute myeloid leukemia: correlation with the cinical-biological, immunophenotypical, and prognostic disease characteristics Ann Hematol 75: 81-86
113. Maruyama Y, Murohashi I, Nara N, Aoki N 1989 Effects of Verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemo-sensitivity of leukemic blast progenitors in acute myelogeneous leukemia. Br J Haematol 72: 357-362
114. Merlin JL, Guerci A, Marchal S, Bour C, Colosetti P, Kataki A, Guerci O 1998 Influence of SDZ-PSC833 on daunomycin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukemia. Br J Haematol 103: 480-487
115. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, Russo D, Vissani G, Pileri S 1992 Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 48: 87-92
116. Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russa D, Lauria F, Masolini P, Baccaruni M 1997 P-glycoprotein (P-gp) and lung resistance protein (LRP) expression and function in leukemic blast cells. Br J Hematol 96: 356-365
117. Michieli M, Damiani D, Ermacora A, Musolini P, Raspadori D, Visani G, Scheper RJ, Baccarani M 1999 P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 104: 328-335
118. Miwa H, Kita K, Morita N, Takakura N, Ohishim K, Mahmud N, Kageyamu S, Fukumoto M, Shirakawa S 1993 Expression of MDR1 gene in acute leukemia cells: association with CD7 positive acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 82: 3445-2451
119. Mizuno Y, Hara T, Nagata M, Tawa A, Tsuruo T, Ueda K 1991 Detection of multidrug-resistant protein, P-glycoprotein in childhood leukaemia and lymphoma. Eur J Pediatr 150: 416-418
120. Neefjes JJ, Momburg F, Hämmerling GJ 1993 Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261: 769-771
121. Nooter K, Westerman AM, Flens MJ, Zaman RJ, Van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P 1995 Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1: 1301-1310
122. Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gullis E, Gieseler F, Bock S, Bartl R, Petrides PE, Wilmanns 1994 Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes- first experience with there reversal. Ann Hematol 69: S25-S29
123. Nussler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gulis E, Sauer H, Wilmanns W 1996 P-glycoprotein expression in patients with acute leukemia - clinical relevance. Leukemia 10: S23-S31
124. Pall G, Spitaler M, Hofman J, Thaler J, Ludescher C 1997 Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia 11: 1067-1072
125. Pallis M, Turzanski J, Wheatley K, Langabeer S, Burmett AK, Russell NH 1999 Use of standardized flow-cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukemia. Br J Haematol 104: 258-265
126. Paul S, Breuninger LA, Tew KD, Shen H, Kruh GD 1996 ATP-dependent uptake of natural product cytotoxic drugs by membrane vesicles establishes MRP as a broad specificity transporter. Proc Natl Acad Sci 93: 6929-6934
127. Pieters R, Huismans DR, Loonen AH, Hählen K, Van der Does-van den Berg A, Van Wering ER, Veerman AJP 1991 Correlation of in vitro drug resistance assessed by the MTT assay with long-term clinical outcome in childhood acute lymphoblastic leukemia. Lancet 338: 399-403
128. Pieters R, Hongo T, Loonen AH, Huismans DR, Broxterman HJ, Hählen K, Veerman AJP 1992 Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukemia. Br J Cancer 65: 691-697
129. Pieters R, Klumper E, Kaspers GJL, Veerman AJP 1997 Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol 25: 11-26
130. Pieters R, DenBoer ML, Kaspers GJL, Janka G, Van Wering ER, Kamps WA, Van der Does-van den Berg, Veerman AJP 1998a Stratification of treatment according to drug resistance profiles in acute lymphoblastic leukemia. Leukemia 12: 262a
131. Pieters R, Den Boer ML, Durian M, Janka-Schaub GE, Schmiegelow K, Kaspers GJL, Van Wering ER, Veerman AJP 1998b Relation between age, immunophenotype, and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants. Leukemia 12: 1344-1348
132. Pirker R, Wallner J, Geisler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K 1993 MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708-712
133. Pirker R, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager R, Geister K, Lechner K, Filipits M 1997 Expression of the lung resistance protein (LRP) predicts poor outcome in de novo acute myeloid leukemia. Blood 90: 2519a
134. Raaijmakers HG, Izquirdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P 1998 Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 91: 1029-1036
135. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G 1990 Modulation of multidrug resistance by verapamil or mdr-1 anti-sense oligodeoxy-nucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human (LoVo) cell line. Int J Cancer 46: 727-732
136. Rome LH, Kedersha NL, Chugani DC 1991 Unlocking vaults: organelles in search of function. Trends Cell Biol 1: 47-50
137. Rome LH 1995 Multidrug resistance: locked in the vault? Nature Med 1: 527
138. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA 1993 Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 82: 1288-1299
139. Ross DD, Doyle CA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deely RG, Yang W, Tong Y 1996 Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 10: 48-55
140. Ross DD, Karp J, Yang W, Gao Y, Abruzzo LV, Doyle LA 1998 Expression of breast cancer resistance protein (BCRP) in blast cells from patients with acute myeloid leukemia. Blood 93: 386a
141. Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack DG, Fojo AT 1989 Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74: 1388-1395
142. Samdani A, Vijapurkur U, Grimm MA, Spier CS, Grogan TM, Glinsmann-Gibson BJ, List AF 1996 Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leukemia Res 20: 175-180
143. Sato H, Gotteman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA, Preisler HD 1990a Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 14: 11-21
144. Sato W, Yuas K, Naito M, Tsuruo T 1990b Staurosporin, a potent inhibitor of C-kinase, enhances drug accumulation in multi-drug resistant cells. Biochem Biophys Res Commun 173: 1252
145. Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grunwald H, Gottlieh A, Bennett J, Gottesman M, Pastan I 1990c MDR1 transcript levels as an indication of resistant disease in acute myelogeneous leukemia. Br J Hemat 75: 340-345
146. Sauerbrey A, Zintl F, Volm M 1994 P-glycoprotein and gluthatione S-transferase p in childhood acute lymphoblastic leukemia: Prognostic implications. Br J Cancer 70: 1144-1149
147. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquirdo MA, Slovak ML, Pinedo HM, Meijer Clevers HC, Scheper RJ 1995 The drug resistance-related protein LRP is the human major vault protein. Nature Med 1: 578-582
148. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Van Heijningen THM, Van Kalken CK, Slovak ML, de Vries EGE, Van der Volk P, Meijer CJLM, Pinedo HM 1993 Overexpression of a M(r) 110.000 vesicular protein non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479
149. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufman SH 1995 Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85: 186-193
150. Schuurhuis GJ, Broxterman HJ, de Lange JHM, Pinedo HM, Van Heijningen THM, Kuiper CM, Scheffer GL, Scheper RJ, Van Kalken CK, Baak JPA, Lankelma J 1991 Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 64: 857-861
151. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Buak JPA, Eekman CA, Kuiper AM, Feller N, Van Heijningen THM, Klumper E, Pieters R, Jankelma J, Pinedo HM 1995 Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res I: 81-93
152. Senent L, Janque I, Martin G, Sempere A, Gonzeles-Garcia Y, Gomis F, Perez-Sirvent M, Rubia J de la, Sanz MA 1998 P-glycoprotein expression and prognostic value in acute myeloid leukemia. Haematologica 83: 783-787
153. Sievers EL, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL, Bernstein ID 1995 Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 pediatric in acute myeloid leukemia fails to define a poor prognostic group. Leukemia 9: 2042-2048
154. Simon SM and Schindler M 1994 Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91: 3497-3504
155. Slovak LS, Ho JP, Cole SPC, Deeley RG, Greenberger L, de Vries EGE, Broxterman HJ, Scheffer GL, Scheper RJ 1995 The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 55: 4214-4219
156. Slapak CA, Mizunuma N, Kufe DW 1994 Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemic cells. Blood 84: 3113-3121
157. Smith PJ, Lihou MG 1986 Prediction of remission induction in childhood acute myeloid leukemia. Aust NZ J Med 16: 39-42
158. Salary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn J, Sadoun A, Pignon B, Berthuo C, Mahisel F, Guyotat D, Casasus P, Ifrah N, Lamy A, Audhuy B, Colombat P, Harousseau 1996 Combination of quinine as a potential reversing agent with mitoxantrone and cytarabin for the treatment of acute leukemias: a randomized multicenter study. Blood 88: 1198-1205
159. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, Van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B 1996 Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 10: 1741-1750
160. Sonneveld P, Wiemer E 1997a Inhibitors of multidrug resistance. Curr Opin Oncol 9: 543-548
161. Sonneveld P, Wiemer E 1997b Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. Leukemia 11: 1160-1165
162. Stasi R 1998 Prognostic value of cytogenetics and multidrug resistance (MDR1) in elderly patients with acute myeloid leukemia. Blood 92: 695-705
163. Tafuri A, Sommaggio A, Burba L, Albergoni MP, Petrucci MT, Testi AM, Basso G 1995 Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Leukemia Res 19: 927-931
164. Takeshita A, Shinjo K, Ohnishi K, Ohno R 1996 Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukemia cells. Br J Haematol 93: 18-21
165. Te Boekhorst PAW, Van Kapel J, Schoester M, Sonneveld P 1992 Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive SDZ PSC in Chinese Hamster Ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmcol 30: 238-242
166. Te Boekhorst PAW, De Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Löwenberg B, Sonneveld P 1993 Predominance of the multidrug resistance gene in myeloid leukemias. Blood 82: 3157-3162
167. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastant, Willingham MC 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735
168. Ubezio P, Limonta M, D'incalci M, Damia G, Masera G, Giudici G, Wolverton JS, Beck WT 1989 Failure to detect the P-glycoprotein multidrug resistance phenotype in cases of resistant childhood acute lymphoblastic leukemia. Eur J Cancer Clin Oncol 25: 1895-1899
169. Van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PAW, Pieters R, Lowenberg B, Sonneveld P 1997 MDR-1 is an independent prognostic factor for response and survival in de novo acute myeloid leukemia. Br J Haematol 99: 76-83
170. Van der Kolk D, de Vries EGE, Koning JA, VandenBerg E, Muller M, Vellenga E 1998 Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res 4: 1727-1736
171. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR 1995 Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82-89
172. Volm M, Stammler G, Zintl F, Koomägi R, Sauerbrey A 1997 Expression of lung-resistance protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia. Anticancer Drugs 8: 662-665
173. Volm M 1998 Multidrug resistance and its reversal. Anticancer Res 18: 2905-2918
174. Vossebeld PJ, Sonneveld P 1999 Reversal of multidrug resistance. Blood Rev 13: 67-78
175. Wattel E, Lepelley P, Meralt A, Sartiaux C, Baulers F, Jouet JP, Fenaux P 1995 Expression of the multidrug resistance P-glycoprotein in newly diagnosed adult lymphoblastic leukemia: absence of correlation with response to treatment. Leukemia 9: 1870-1874
176. Wiemer E, Schoester M, Sonneveld P 1998 Intracellular lozalisation and dynamics of the vault complex in non-Pgp multidrug resistant cell lines. Blood 92: 676a
177. Willman CL 1997 The prognostic significance of the expression and function of multidrug resistance proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Programm. Semin Hematol 34 (4 Suppl 5): 25-33
178. Wood P, Burgess R, McGregor A, Liu Yin JA 1994 P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 87: 509-514
179. Xu D, Knaust E, Pisa P, Palucka K, Lundeberg J, Arestrom I, Peterson C, Gruber A 1996 Levels of mdr1 and mrp mRNA in leucaemic cell populations from patients with acute myelocytic leucaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation. Br J Haematol 92: 847-854
180. Zaman GJR, Flens MJ, Van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P 1994 The human multidrug resistance associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826
181. Zhou DC, Marie JP, Suberville AM, Zittoun R 1992 Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 6: 879-885
182. Zhou DC, Zittoun R, Marie JP 1995 Expression of multidrug resistance-associated protein (MRP) and multidrug resistance genes (MDR1) genes in acute myeloid leukemia. Leukemia 9: 1661-1666
183. Zochbauer S, Gsur A, Brunner R, Kyrie PA, Lechner K, Pirker R 1994 P-glycoprotein expression as a favorable prognostic factor in acute myeloid leukemia. Leukemia 8: 974-977